Rainer M, Brunnbauer M, Dunky A, Ender F, Goldsteiner H, Holl O, Kotlan P, Paulitsch G, Reiner C, Stössl J, Zachhuber C, Mössler H
Donauspital im SMZ-Ost der Stadt Wien, Vienna.
Wien Med Wochenschr. 1997;147(18):426-31.
In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin. The effectiveness of the therapy was examined under conditions of daily clinical practice.
645 Patients were treated with 30 ml Cerebrolysin daily. The average period of treatment was 17.8 days. Prior to treatment patients were diagnosed according to DSM-III-R. In addition a differential diagnostic examination using the Hachinski Ischemic Score was performed. Clinical symptoms and the Clinical Global Impression (CGI) were determined before and after therapy.
Cerebrolysin therapy led to a significant (p < 0.001) improvement in memory for 62% of the patients. 65% showed improvement in concentration, 50% in mood and fatigue, and 47% improved in vertigo. An improvement in the Clinical Global impression was observed in approximately 80% of the patients. The improvement of symptoms was significantly larger (p < 0.05) in younger, less afflicted patients than in the older, more seriously ill patients. The unusual good tolerance of Cerebrolysin was especially noteworthy.
The present study confirms the results of earlier clinical studies with Cerebrolysin in the treatment of Alzheimer patients and patients with vascular dementia in which similar responder rates were observed. The significant dependence of therapeutic success on the length and severity of illness confirms that timely pharmacological intervention leads to best therapeutic results.
在本研究中，患有痴呆症的患者接受了使用神经营养药物脑蛋白水解物的输液治疗。在日常临床实践条件下对该治疗的有效性进行了检查。
645例患者每天接受30毫升脑蛋白水解物治疗。平均治疗期为17.8天。治疗前根据《精神疾病诊断与统计手册》第三版修订本（DSM-III-R）对患者进行诊断。此外，使用哈金斯基缺血评分进行了鉴别诊断检查。在治疗前后确定临床症状和临床总体印象（CGI）。
脑蛋白水解物治疗使62%的患者记忆力有显著（p < 0.001）改善。65%的患者注意力得到改善，50%的患者情绪和疲劳状况改善，47%的患者眩晕症状改善。约80%的患者临床总体印象有改善。较年轻、病情较轻的患者症状改善明显大于（p < 0.05）年龄较大、病情较重的患者。脑蛋白水解物异常良好的耐受性尤其值得注意。
本研究证实了早期使用脑蛋白水解物治疗阿尔茨海默病患者和血管性痴呆患者的临床研究结果，其中观察到了相似的有效率。治疗成功对病程长度和疾病严重程度的显著依赖性证实了及时的药物干预可带来最佳治疗效果。
